TURKEL CATHERINE C. 4
4 · Novus Therapeutics, Inc. · Filed May 22, 2019
Insider Transaction Report
Form 4
TURKEL CATHERINE C.
Chief Development Officer
Transactions
- Sale
Common Stock
2019-05-20$1.96/sh−7,623$14,953→ 90,576 total - Sale
Common Stock
2019-05-21$1.91/sh−1,914$3,658→ 88,662 total
Footnotes (3)
- [F1]Shares were sold to cover the reporting person's taxes due on the vesting of restricted stock units.
- [F2]This transaction was executed in multiple trades at prices ranging from $1.90 to $2.05. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $1.90 to $1.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.